Comment devenir CCA en un WE? HPN aplasie médullaire
|
|
- Randolf Austin
- 6 years ago
- Views:
Transcription
1 Comment devenir CCA en un WE? HPN aplasie médullaire Régis Peffault de Latour, MD, PhD Saint Louis Hospital, Paris; AIH 27 Septembre 2014
2 Paroxysmal Nocturnal Hemoglobinuria (PNH): Acquired hemolytic anemia Thrombosis +/- aplastic anaemia Rare disease: Prevalence: 15.9 / million 1 Young patients: median age early 30 s 3-5 Severe disease: median overall survival 22 years 1. Hill A et al. Blood. 2006;108(11):290a. Abstract Hillmen P et al. N Engl J Med. 1995;333: Nishimura JI, et al. Medicine. 2004;83: Socié G et al. Lancet. 1996;348: Peffault de Latour et al. Blood; 112:
3 Survival Mortality rate in PNH: Data From French Patients 1 8 O/N* 96/ (0.03) 10-year survival rate (SE) Time after diagnosis (years) n Peffault de Latour et al. Blood 2008; 112:
4 Pathophysiology Somatic mutations in the PIG- A gene Protein NH 2 NH 2 Phosphoethanolamine Glycan core O (a 1-6) O MA N (a 1-2) C=O NH CH 2 CH 2 O O-P-O- O MAN Extracellular COOH Phosphatidylinositol GPI anchor structure H 2 C O H C O O O=P-O CH O 2 O C=O GLU N C=O INOS MAN COOH Deficit in GPIanchored proteins Intracellular PNH, paroxysmal nocturnal haemoglobinuria; PIG-A, phosphatidylinositol glycan class A; GPI, glycosylphosphatidylinositol Young NS et al. Hematology Am Soc Hematol Educ Program 2000:18 38
5 GPI deficiency results in Hemolytic Anemia (lack of CD59 or CD55) C5 convertase C5 convertase Absence of CD59 allows terminal complement complex formation C9 C9 x C5 C5a C6 C7 C5b C6 C5b C8 C6 C5b X C6 C5b X C6 C5b C7 C7 CD59 C7 CD59 C7 C8 C8 C9 C8 C5b-9 C5b,6,7 C5b-8 PNH, paroxysmal nocturnal haemoglobinuria Adapted from Abbas AK et al. Cellular and Molecular Immunology, 3rd ed. WB Saunders: Philadelphia, 1991
6 Historically Viewed as a Hemolytic Anemia Normal red blood cells are protected from complement attack by a shield of terminal complement inhibitors Without this protective complement inhibitor shield, PNH red blood cells are destroyed Complement Activation Intact RBC Reduced Free Hemoglobin Red Cell Mass Anemia 1. International PNH Interest Group. Blood. 2005;106: Brodsky R Paroxysmal Nocturnal Hemoglobinuria. In: Hematology - Basic Principles and Practices. 4th ed. R Hoffman; EJ Benz; S Shattil et al, eds. Philadelphia, PA: Elsevier Churchill Livingstone; 2005; Rother RP et al. JAMA. 2005;293: Socie G et al. Lancet. 1996;348: Hill A et al. Br J Haematol. 2007;137:
7 How best to treat PNH & AA in 2014
8 PNH management in 2014 PNH Hemolytic PNH AA / PNH AA Hemolysis Moderate AA No Hemolysis Severe AA No Hemolysis Eculizumab IST SCT THROMBOSIS
9 PNH management in 2014 PNH Hemolytic PNH AA / PNH AA Hemolysis Moderate AA No Hemolysis Severe AA No Hemolysis Eculizumab IST SCT THROMBOSIS
10 Mr FE. CA. 31 ans 2011: Premier episode de douleurs abdominales Une taille de clone de 30% sur les globules rouges : Crises hémolytiques & transfusions mensuelles Nausées et vomissements Fatigue Difficulté à se concentrer 2400 olynucléaires & plaquettes Son frère est HLA identique
11 Answers (n) Quelle est votre attitude? Eculizumab 2 - Prophylaxie Anti-thrombotique 3 - Supplémentation en folates et en fer 4 - Immunosuppression: ATG + cyclosporine 5 - Greffe de moelle
12 Answers (n) Quelle est votre attitude? 1 - Eculizumab 0% 2 - Prophylaxie Anti-thrombotique 0% 3 - Supplémentation en folates et en fer 0% 4 - Immunosuppression: ATG + cyclosporine 0% 5 - Greffe de moelle 0%
13 Survie Mortality With Best Supportive Care In Hemolytic PNH Patients 1 Intermediate (n=93) Classic Hb <12g/dl and/or thrombosis (n=113) French cohort (n=460) AA-PNH Intermediate PNH Classic PNH Temps (années) 30 AA PNH syndrome 2 or 3 lineages* *Hb 10g/dl, Platelets 80 g/l, Neutrophiles 1 g/l (n=224) Socié et al, Lancet 1996; Peffault de Latour, RP et al, Blood. 2008;112(8):
14 Mortality With Transplantation In Hemolytic PNH Patients EBMT cohort (n=211) - Hemolytic (n=64) - Aplastic anemia (n=100) - Thrombosis (n=47) Peffault de Latour, et al. Haematologica. 2012
15 Mortality With Transplantation In Hemolytic PNH Patients EBMT cohort (n=211) - Hemolytic (n=64) - Aplastic anemia (n=100) - Thrombosis (n=47) Transplantation - GvHD - Acute, CI = 65% - Chronic, CI = 45% - Causes of death (n=64) - GvHD - Infections Peffault de Latour, et al. Haematologica. 2012
16 Cumulative Surviving (%) Mortality With Eculizumab In Hemolytic PNH Patients 100 Eculizumab n = Untreated n = Long-term follow-up needed!! Time (years) Kelly RJ et al. Blood. 2011
17 Quelle est votre attitude? 1 - Eculizumab 2 - Prophylaxie Anti-thrombotique 3 - Supplémentation en folates et en fer 4 - Immunosuppression: ATG + cyclosporine 5 - Greffe de moelle
18 Quelle est votre attitude? 1 - Eculizumab 2 - Prophylaxie Anti-thrombotique 3 - Supplémentation en folates et en fer 4 - Immunosuppression: ATG + cyclosporine 5 - Greffe de moelle
19 PNH management in 2014 PNH Hemolytic PNH AA / PNH AA Hemolysis Moderate AA No Hemolysis Severe AA No Hemolysis Eculizumab IST SCT THROMBOSIS
20 PNH management in 2014 PNH Hemolytic PNH AA / PNH Moderate AA Hemolysis Moderate AA No Hemolysis Severe AA No Hemolysis Eculizumab IST SCT THROMBOSIS
21 Mr JE. RE. 22 ans 2011: Aplasie médullaire modérée non transfusé Une taille de clone de 13% sur les globules rouges : Transfusé de plus en plus souvent en plaquettes Clone augmente 50% (LDH normales) Pas de donneur familial HAL compatible
22 Answers (n) Mr JE. RE. 22 ans Eculizumab 2 - Prophylaxie Anti-thrombotique 3 - Supplémentation en folates et en fer 4 - Immunosuppression: ATG + cyclosporine 5 - Greffe de moelle
23 Answers (n) Mr JE. RE. 22 ans 1 - Eculizumab 0% 2 - Prophylaxie Anti-thrombotique 0% 3 - Supplémentation en folates et en fer 4 - Immunosuppression: ATG + cyclosporine 5 - Greffe de moelle 0% 0% 0%
24 AA and treatment Severe (SAA) Hypocellularity (<30%) & At least 2/3 critèria: PNN <0.5x10 9 /L Platelets <20x10 9 /L Reticulocytes <20x10 9 /L Very severe (vsaa) PNN <0.2x10 9 /L Moderate Not all criteria for SAA PNN >0.5x10 9 /L Yes Transfusions? No Treatment Follow-up Camitta et al. Blood 1976
25 AA and sibling donor HSCT for SAA; young patients and HLA-identical sibling Donor Marrow =<20 years(rr 2.4) p=0.02 >20 years(rr 1.2) p= BM, 20 yrs, N = 308, 85% PB, 20 yrs, N = 49, 73% PB, 20 yrs, N = 49, 27% 20 0 BM, 20 yrs, N = 307, 12% Schrezenmeier et al Blood 2007
26 AA and sibling donor HSCT for SAA; young patients and HLA-identical sibling Donor Marrow Cy- ATG Blood. 2007;109:
27 AA and sibling donor HSCT for SAA; young patients and HLA-identical sibling Donor Marrow Cy- ATG CsA + MTX Blood. 2000;96:
28 AA and sibling donor>bmt! HSCT for SAA; young patients and HLA-identical sibling Donor Event No of Events 6yr-CI (%) Secondary Cancer 1 2 (0-9) 87,5 % (IC 95%, 78-97) Osteonecrosis (10-36) Cardiovascular complications Endocrine dysfunctions 1 2 (0-9) 7 19 (9-31) Saint Louis experience Haematologica 2012
29 AA and no sibling donor
30 AA and no sibling donor Phase III prospective randomized study First-line treatment hatg + CyA (n=60) vs ratg + CyA (n=60) OR at 6m 68% vs 37% (p<0.001) Phase II prospective study First-line treatment ratg + CyA (n=35) OR at 6m 40% Scheinberg P, NEJM, 2011; Marsh JC, Blood 2012
31 Answers (n) Mr JE. RE. 22 ans 1 - Eculizumab 2 - Prophylaxie Anti-thrombotique 3 - Supplémentation en folates et en fer 4 - Immunosuppression: ATG + cyclosporine 5 - Greffe de moelle
32 Answers (n) Mr JE. RE. 22 ans 1 - Eculizumab 2 - Prophylaxie Anti-thrombotique 3 - Supplémentation en folates et en fer 4 - Immunosuppression: ATG + cyclosporine 5 - Greffe de moelle
33 PNH management in 2014 PNH Hemolytic PNH AA / PNH Moderate AA Hemolysis Moderate AA No Hemolysis Severe AA No Hemolysis Eculizumab IST No Sib. SCT Sib. THROMBOSIS
34 PNH management in 2014 PNH Hemolytic PNH AA / PNH AA Hemolysis Moderate AA No Hemolysis Severe AA No Hemolysis Eculizumab IST No Sib. SCT Sib. THROMBOSIS
35 PNH management in 2014 PNH Hemolytic PNH AA / PNH AA Hemolysis Moderate AA No Hemolysis Severe AA No Hemolysis Eculizumab IST No Sib. SCT Sib. THROMBOSIS
36 PNH management in 2014 PNH Hemolytic PNH AA / PNH Moderate AA Hemolysis Moderate AA No Hemolysis Severe AA No Hemolysis Eculizumab IST No Sib. SCT Sib. THROMBOSIS
37 Mr RE. PE. Homme de 31 ans Avril 1998: Le diagnostic d HPN est fait Urine foncée Dysphagie Pas de transfusions Hb 9 g/dl, GB 5.3 x 10 9 /l, Plts 219 x 10 9 /l 99.5% de neutros HPN 37% de GR HPN
38 Mr RE. PE. Decembre 2006: Douleurs abdominales d apparition aiguë Ascite > Syndrome de Budd-Chiari
39 Mr RE. PE. Unité de soins intensifs Feeling extremely unwell Encephalite Fièvre HBPM Antibiotiques TIPS (transjugular intrahepaticportosystemic shunt) Fin d hospitalisation
40 Mr RE. PE. Réhospitaliser en aout 2007 avec des douleurs abdominles aiguës Ascite Extension de la thrombose de la veine hépatique Sep 2007.
41 Mr RE. PE. Eculizumab a été débuté. Schéma posologique classique. Transformé! Aujourd hui: Toujours sous eculizumab Suivi régulier toutes les 2 semaines Que faire de l anticoagulation?
42 Answers (n) Mr RE. PE Stop anticoagulatio et poursuite de l ecullizumab 2 - Stop eculizumab et anticoagulation 3 - Eculizumab et anticoagulation à vie 4 - Augmentation eculizumab à 1200mg et anticoagulation à vie 5 - Greffe de moelle
43 Answers (n) Mr RE. PE. 1 - Stop anticoagulatio et poursuite de l ecullizumab 2 - Stop eculizumab et anticoagulation 3 - Eculizumab et anticoagulation à vie 4 - Augmentation eculizumab à 1200mg et anticoagulation à vie 5 - Greffe de moelle 0% 0% 0% 0% 0%
44 Cumulative incidence Thrombosis in PNH Thrombosis risk factors RR p Thrombosis 10-year CI 37.9% Age >55 years year CI 27.3% Thrombosis (at diagnosis) Warfarin (prophylaxis) Transfusions Immunosuppressive therapy <0.001 < year CI 27.8% Aplastic anaemia PNH Intermediate PNH Classical PNH Years 55% (10/18) had a TE while on prophylactic anticoagulation 1 1.Peffault de Latour, RP et al. Blood. 2008;112(8):
45 Hazard Ratio Thrombosis is Associated With Risk of Early Mortality TE increases risk of death 15-fold over patients with no TE Patients (n=415) TE was an independent prognostic factor related to poor survival (HR 15.4; 95% CI ; P<0.001) in a large cohort of French PNH patients 1. Peffault de Latour R et al. Blood. 2008;112(8):
46 Thrombotic Events (#) Thrombosis and Eculizumab Pre-Eculizumab Treatment N=195 P= Eculizumab Treatment 63% of patients received concomitant anticoagulants Both venous and arterial sites There were fewer thrombotic events with Eculizumab treatment than during the same period of time prior to treatment Brodsky R et al. Blood. 2008
47 Thrombosis and Transplantation SFH EBMT Non grafted SCT Not confirmed 2 Date? 2 Severity? 2 F-up<6mo post Thr MDS before 1 24 Matched pairs Overall Survival (OS) 10 Non Grafted SCT p Log Rank =.01 p Cox stratified on pairs =.007 HR SCT/non grafted = 10.0( ) Time since thrombosis (year) Peffault de Latour et al, Haematologica 2012
48 Answers (n) Mr RE. PE. 1 - Stop anticoagulatio et poursuite de l ecullizumab 2 - Stop eculizumab et anticoagulation 3 - Eculizumab et anticoagulation à vie 4 - Augmentation eculizumab à 1200mg et anticoagulation à vie 5 - Greffe de moelle
49 Answers (n) Mr RE. PE. 1 - Stop anticoagulatio et poursuite de l ecullizumab 2 - Stop eculizumab et anticoagulation 3 - Eculizumab et anticoagulation à vie 4 - Augmentation eculizumab à 1200mg et anticoagulation à vie 5 - Greffe de moelle
50 PNH management in 2014 PNH Hemolytic PNH AA / PNH Moderate AA Hemolysis Moderate AA No Hemolysis Severe AA No Hemolysis Eculizumab IST No Sib. SCT Sib. THROMBOSIS
51 And what about pregnancy & PNH French experience (26 pregnancies/20 patients) - Cytopenia during pregnancy (90%) - Thrombosis at time of delivery and in the post-partum (4 severe complications/20 with 2 deaths!!) - Prematurity in 30% de Guibert et al, Haematologica 2010
52 And what about pregnancy & PNH French experience (26 pregnancies/20 patients) - Cytopenia during pregnancy (90%) - Thrombosis at time of delivery and in the post-partum (4 severe complications/20 with 2 deaths!!) - Prematurity in 30% Guidelines - Low weight heparin from 6 months to 3 months postpartum + Eculizumab de Guibert et al, Haematologica 2010
53 And what about pregnancy & PNH French experience (26 pregnancies/20 patients) - Cytopenia during pregnancy (90%) - Thrombosis at time of delivery and in the post-partum (4 severe complications/20 with 2 deaths!!) - Prematurity in 30% Guidelines - Low weight heparin from 6 months to 3 months postpartum + Eculizumab International study on going - Almost 80 cases - Abstract for ASH de Guibert et al, Haematologica 2010
54 Take home messages PNH Hemolytic PNH AA / PNH Moderate AA Hemolysis Moderate AA No Hemolysis Severe AA No Hemolysis Eculizumab IST No Sib. SCT Sib. THROMBOSIS
55 Merci! Centre Ref. Aplasie Médullaire (Pr Socié) SFH Participating centers
Pathophysiology 7/18/2012 PAROXYSMAL NOCTURNAL HEMOGLOBINURIA
PAROXYSMAL NOCTURNAL HEMOGLOBINURIA OUTLINE OF DISCUSSION WHAT IS IT WHO GETS IT NATURAL HISTORY TYPES RISKS COURSE TREATMENTS SYMPTOMS PREGNANCY Pathophysiology Acquired hematopoietic stem cell disorder
More informationPNH PNH PNH 3/22/2016 PNH. Paroxysmal Nocturnal Hemoglobinuria (PNH): Current Thinking on the Disease PATHOGENESIS OF PNH
3//1 PATHGENESIS F PIG-A gene Bone Marrow Failure Disease Scientific Symposium Rockville, March 17-1, 1 1 71 9 3 Paroxysmal Nocturnal Hemoglobinuria (): Current Thinking on the Disease 119 5 15 PRTEIN
More information9/19/2017. PNH Understanding your diagnosis and treatment. Paroxysmal Nocturnal Hemoglobinuria (PNH) Paroxysmal Nocturnal Hemoglobinuria
August_20_2010US Patients Surviving (%) Paroxysmal Nocturnal Hemoglobinuria (PNH) PNH Understanding your diagnosis and treatment Hugo Castro-Malaspina, MD Memorial Sloan Kettering Cancer Center New York,
More information3/31/2014 PNH. Jack Goldberg MD FACP. Clinical Professor of Medicine University of Pennsylvania
PNH Jack Goldberg MD FACP Clinical Professor of Medicine University of Pennsylvania 1 2 3 4 1 5 6 Historically Viewed as a Hemolytic Anemia Normal red blood cells are protected from complement attack by
More informationLiving with PNH 7/3/2013. Paroxysmal Nocturnal Hemoglobinuria (PNH): A Chronic, Systemic, and Life- Threatening Disease
Living with PNH Laurence A. Boxer, MD University of Michigan Case Study 15 year old awakened in the morning with chest pain and a sore throat. She experienced chest pain all day accompanied with coughing
More informationThe use of the complement inhibitor eculizumab (Soliris R ) for treating Korean patients with paroxysmal nocturnal hemoglobinuria
VOLUME 45 ㆍ NUMBER 4 ㆍ December 2010 THE KOREAN JOURNAL OF HEMATOLOGY ORIGINAL ARTICLE The use of the complement inhibitor eculizumab (Soliris R ) for treating Korean patients with paroxysmal nocturnal
More informationAcknowledgments. Michael Brown Petra Muus for case reports
Current treatment strategy for PNH Jeff Szer Professor/Director, Department of Clinical Haematology & BMT Service The Royal Melbourne Hospital Australia Acknowledgments Michael Brown Petra Muus for case
More informationParoxysmal Nocturnal Hemoglobinuria
Paroxysmal Nocturnal Hemoglobinuria Jun Ho Jang, M.D., Ph.D. Professor, Division of Hematology-Oncology, Samsung Medical Center Sungkyunkwan University School of Medicine, Seoul, Korea Contents 1. Disease
More informationYes Antonio M. Risitano, M.D., Ph.D. Head of Bone Marrow Transplantation Unit Federico II University of Naples
4ème Journée Nationale Maladies Rares Immuno-Hématologiques Paris, June 7th 2018 Matched unrelated upfront transplantation in idiopathic aplastic anemia? Yes Antonio M. Risitano, M.D., Ph.D. Head of Bone
More informationWhat is PNH? PNH: What it is Not 9/11/2015. What is Paroxysmal Nocturnal Hemoglobinuria?
9/11/15 PNH: Current Thinking on the Disease, Diagnosis, and Treatment Joseph H. Antin, MD Professor of Medicine Harvard Medical School Jock and Bunny Adams Chair in Hematology Dana-Farber/Brigham and
More informationNot So Benign Hematology Aplastic anemia, Paroxysmal Nocturnal Hemoglobinuria, atypical Hemolytic Uremic Syndrome, Thrombotic Thrombocytopenic Purpura
Not So Benign Hematology Aplastic anemia, Paroxysmal Nocturnal Hemoglobinuria, atypical Hemolytic Uremic Syndrome, Thrombotic Thrombocytopenic Purpura Robert A. Brodsky, MD Johns Hopkins Family Professor
More informationPNH. What is PNH? 7/12/2016 PNH. What is PNH? 1 st published case report of PNH
AA-MDS Patient Conference Raleigh / Durham July 016 : Current Thinking on the Disease, Diagnosis, and Treatment What is? What causes? What are the clinical symptoms of? How is diagnosed? What are the long-term
More information9/19/2012. Case study. Case study PNH: A REVIEW AND AN UPDATE
PNH: A REVIEW AND AN UPDATE Jamile M. Shammo MD, FASCP, FACP Associate Professor of Medicine and Pathology Rush University Medical Center Chicago Case study A 37 year old man was referred to the hematology
More informationUnderstanding and Managing Long- Term and Late Issues in PNH. Outline
Understanding and Managing Long- Term and Late Issues in PNH AA & MDS International Foundation Regional Patient and Family Conference Cleveland, Ohio Ramon V. Tiu, MD Cleveland Clinic Taussig Cancer Institute
More informationMUD HSCT as first line Treatment in Idiopathic SAA. Dr Sujith Samarasinghe Great Ormond Street Hospital for Children, London, UK
MUD HSCT as first line Treatment in Idiopathic SAA Dr Sujith Samarasinghe Great Ormond Street Hospital for Children, London, UK No Financial Disclosures Guidelines for management of aplastic anaemia British
More informationImmunosuppressive treatment in acquired aplastic anemia. André Tichelli Hematology, University Hospital Basel
Immunosuppressive treatment in acquired aplastic anemia André Tichelli Hematology, University Hospital Basel Why is immunosuppressive treatment a choice for acquired aplastic anemia? Hematopoietic stem
More information7/26/2013. The Defect in PNH PNH: NEW DIRECTIONS IN PNH TREATMENT. Paroxysmal Nocturnal Hemoglobinuria: Survival
PNH: NEW DIRECTIONS IN PNH TREATMENT Jamile M. Shammo MD, FASCP, FACP Associate Professor of Medicine and Pathology Rush University Medical Center Chicago Paroxysmal Nocturnal Hemoglobinuria: Survival
More informationSOLIRIS is a Complement Inhibitor Indicated for the Treatment of Patients With PNH to Reduce Hemolysis
SOLIRIS (eculizumab) SOLIRIS is a Complement Inhibitor Indicated for the Treatment of Patients With PNH to Reduce Hemolysis SOLIRIS is the First and Only Approved Therapy for PNH SOLIRIS (eculizumab) [package
More informationParoxysmal Nocturnal Hemoglobinuria
Paroxysmal Nocturnal Hemoglobinuria Current Thinking On the Disease Diagnosis and Treatment Ilene Ceil Weitz, MD Associate Clinical Professor of Medicine Jane Anne Nohl Division of Hematology Keck-USC
More information7/14/2014. SOLIRIS (eculizumab) SOLIRIS PNH Clinical Studies. SOLIRIS Blocks Terminal Complement. 86% Reduction in LDH: TRIUMPH and SHEPHERD
Proximal Terminal Lactate Dehydrogenase (U/L) 7/1/1 SOLIRIS (eculizumab) Humanized First in Class Anti - C5 Antibody SOLIRIS (eculizumab) Human Framework Regions No mutations Germline SOLIRIS is a Complement
More informationSlide # 1. What is PNH and what is the long term outlook? Carlos M. de Castro, MD Duke University Medical Center. October 2012 AA&MDSIF Conference
PNH: Complications and Long-Term Issues Carlos M. de Castro, MD Duke University Medical Center October 2012 AA&MDSIF Conference PNH: Comlications and Long-Term Issues What happens to PNH patients? What
More informationNot So Benign Hematology. Robert A. Brodsky, MD Johns Hopkins Family Professor of Medicine and Oncology Division Chief Hematology
Not So Benign Hematology Robert A. Brodsky, MD Johns Hopkins Family Professor of Medicine and Oncology Division Chief Hematology Disclosures Dr. Brodsky serves as a Scientific Advisory Board member to:
More informationeculizumab, 300mg concentrate for solution for infusion (Soliris ) SMC No. (436/07) Alexion Pharma UK Ltd
eculizumab, 300mg concentrate for solution for infusion (Soliris ) SMC No. (436/07) Alexion Pharma UK Ltd 8 October 2010 (Amended 11 July 2011) The Scottish Medicines Consortium (SMC) has completed its
More informationParoxysmal nocturnal hemoglobinuria clones in severe aplastic anemia patients treated with horse anti-thymocyte globulin plus cyclosporine
Paroxysmal nocturnal hemoglobinuria clones in severe aplastic anemia patients treated with horse anti-thymocyte globulin plus cyclosporine Phillip Scheinberg, Michael Marte, Olga Nunez, and Neal S. Young
More informationTherapeutic Advances in Treatment of Aplastic Anemia. Seiji Kojima MD. PhD.
Therapeutic Advances in Treatment of Aplastic Anemia Seiji Kojima MD. PhD. Department of Pediatrics Nagoya University Graduate School of Medicine Chairman of the Severe Aplastic Anemia Working Party Asia-Pacific
More informationNot So Benign Hematology. Robert A. Brodsky, MD Johns Hopkins Family Professor Director of Adult Hematology
Not So Benign Hematology Robert A. Brodsky, MD Johns Hopkins Family Professor Director of Adult Hematology Disclosures Dr. Brodsky serves as a Scientific Advisory Board member to: Alexion Pharmaceuticals
More informationSOLIRIS (eculizumab) Slide # 1. How do we treat PNH?
Treating PNH How do we treat PNH? Hemolytic anemia Iron, folic acid Transfusion Steroids Eculizumab Thrombosis Coumadin prophylaxis Acute treatment with lytic agents (clot busters) Anticoagulation therapy
More informationPNH: Current Thinking on the Disease, Diagnosis and Treatment. What is PNH? 7/6/2009. Paroxysmal sudden onset Nocturnal
PNH: Current hinking on the Disease, Diagnosis and reatment Jaroslaw Maciejewski, MD, PhD Cleveland Clinic Carlos M. de Castro, MD Duke University Medical Center Paroxysmal sudden onset Nocturnal occuring
More informationLatest results of sibling HSCT in acquired AA. Jakob R Passweg
Latest results of sibling HSCT in acquired AA Jakob R Passweg Impact on Outcome: Patient Age, Disease Severity Title: Optimization of Therapy for Severe Aplastic Anemia Based on Clinical, Biological and
More informationThe function of the bone marrow. Living with Aplastic Anemia. A Case Study - I. Hypocellular bone marrow failure 5/14/2018
The function of the bone marrow Larry D. Cripe, MD Indiana University Simon Cancer Center Bone Marrow Stem Cells Mature into Blood Cells Mature Blood Cells and Health Type Function Term Red Cells Carry
More informationKey terms: aplastic anemia; complement inhibitors; paroxysmal nocturnal hemoglobinuria
Cytometry Part B (Clinical Cytometry) 94B:16 22 (2018) Original Article ICCS/ESCCA Consensus Guidelines to detect GPI-deficient cells in Paroxysmal Nocturnal Hemoglobinuria (PNH) and related Disorders
More informationShould we still use Camitta s criteria for severe aplastic anemia?
VOLUME 47 ㆍ NUMBER 2 ㆍ June 2012 THE KOREAN JOURNAL OF HEMATOLOGY ORIGINAL ARTICLE Should we still use Camitta s criteria for severe aplastic anemia? Hyun Hwa Yoon, Seok Jae Huh, Ji Hyun Lee, Suee Lee,
More informationShall young patients with severe aplastic anemia without donors receive BMT from alternative source of HCT? Elias Hallack Atta, MD, PhD
Shall young patients with severe aplastic anemia without donors receive BMT from alternative source of HCT? Elias Hallack Atta, MD, PhD Declaração de Conflito de Interesse Declaro que possuo conflito de
More informationPacientes jovens sem doador com anemia aplástica grave devem receber TMO de fonte alternativa de CTH NO!
Pacientes jovens sem doador com anemia aplástica grave devem receber TMO de fonte alternativa de CTH NO! Phillip Scheinberg, MD Head, Clinical Hematology Hospital A Beneficência Portuguesa de Sao Paulo
More informationSlide # 1. PNH: Comlications and. Long-Term Issues. Long-Term Issues. What is PNH and what is the long term outlook?
PNH: Complications and Long-Term Issues Carlos M. de Castro, MD Duke University Center What happens to PNH patients? PNH: Comlications and Long-Term Issues What are the long-term complications of PNH and
More informationAbdominal pain in combination with an unexplained hemolytic anemia are crucial signs to test for paroxysmal nocturnal hemoglobinuria: A case report
Received: 22 January 2018 Revised: 25 April 2018 DOI: 10.1002/ccr3.1771 Accepted: 9 June 2018 CASE REPORT Abdominal pain in combination with an unexplained hemolytic anemia are crucial signs to test for
More informationBor-Sheng Ko. Hematology Division, Department of Internal Medicine, National Taiwan University Hospital
Bor-Sheng Ko Hematology Division, Department of Internal Medicine, National Taiwan University Hospital On behalf of Members of Aplastic Anemia Consensus Meeting Diagnosis and classification: Treatment
More informationPNH. PNH A study case 5/9/2012. PNH Current Thinking on the Disease, Diagnosis, and Treatment. Where have we been, where are we going?
PNH Current Thinking on the Disease, Diagnosis, and Treatment Where have we been, where are we going? Carlos M. de Castro, MD Duke University Medical Center PNH Case What is PNH? What causes PNH? Relationship
More informationOutline. What is aplastic anemia? 9/19/2012. Aplastic Anemia Current Thinking on the Disease, Diagnosis, and Non-Transplant Treatment Options
Aplastic Anemia Current Thinking on the Disease, Diagnosis, and Non-Transplant Treatment Options Carlos M. de Castro, MD Duke University Medical Center Outline What is Aplastic Anemia? What other diseases
More informationPNH Screening in Patients with Recurrence of Thrombosis during Anticoagulant Therapy
PNH Screening in Patients with Recurrence of Thrombosis during Anticoagulant Therapy PI: Prof. Anna Falanga Bergamo Italy Prof. Anna Falanga Page 1of 9 Introduction Scientific background Genetic basis
More informationEfficacy of eculizumab in paroxysmal nocturnal hemoglobinuria patients with or without aplastic anemia: prospective study of a Korean PNH cohort
BLOOD RESEARCH VOLUME 52 ㆍ NUMBER 3 September 2017 ORIGINAL ARTICLE Efficacy of eculizumab in paroxysmal nocturnal hemoglobinuria patients with or without aplastic anemia: prospective study of a Korean
More informationNew Phase III Clinical Trial Enrolling Now
New Phase III Clinical Trial Enrolling Now Paroxysmal Nocturnal Hemoglobinuria (PNH) Designed for Patients 1. At least 18 years of age 2. With a primary diagnosis of PNH confirmed by high-sensitivity flow
More information3/31/2014. New Directions in Aplastic Anemia Treatment: What s on the Horizon? Objectives
New Directions in Aplastic Anemia Treatment: What s on the Horizon? AA & MDS International Foundation Living with, MDS, or PNH Patient and Family Conferences in 2014 April 5, 2014 Objectives To provide
More informationParoxysmal Nocturnal Hemoglobinuria
Paroxysmal Nocturnal Hemoglobinuria Barry Skikne MD, FACP, FCP(SA) Professor of Hematology Division of Hematologic Malignancies and Cellular Therapeutics Cardinal Clinical Manifestations PNH Clonal disease
More informationCASE REPORT Assessing donor chimerism using flow cytometry in paroxysmal nocturnal haemoglobinuria after stem cell transplantation - a case report
Malaysian J Pathol 2006; 28(2) : 107 112 CASE REPORT Assessing donor chimerism using flow cytometry in paroxysmal nocturnal haemoglobinuria after stem cell transplantation - a case report R Z Azma, MBBS,
More information1/26/12. Selected Topics in Pediatric Hematology/Oncology COMPLEMENTOLOGY OBJECTIVES. Classically Different Topics but not so much
1/26/12 OBJECTIVES Selected Topics in Pediatric Hematology/Oncology COMPLEMENTOLOGY Chatchawin Assanasen MD Recognize implications of complement pathway diseases Signs and symptoms of PNH and ahus Complications
More informationPNH Glossary of Terms
AA Absolute neutrophil count Alendronate Allergen ALT Anemia Antibodies Anticoagulant Anticoagulation Antigen Antithymocyte globulin (ATG) Aplastic Aplastic anemia Band Bilirubin Blast cells Bone marrow
More information9/9/2015 HISTORY & EPIDEMIOLOGY. Objectives. Textbook Definition of Aplastic anemia (AA) Epidemiology. History
Objectives Aplastic Anemia: Current Thinking on the Disease, Diagnosis, and Non-Transplant Treatment Amy E. DeZern, MD, MHS Assistant Professor of Oncology and Medicine The Johns Hopkins University School
More information4/17/2018. Paroxysmal Nocturnal Hemoglobinuria: Paroxysmal Nocturnal Hemoglobinuria. Epidemiology. PNH Stem Cell.
Paroxysmal Nocturnal Hemoglobinuria: Understanding the Diagnosis, Complications and Treatment Options Iberia Romina Sosa, MD, PhD Assistant Professor of Medicine Baylor College of Medicine April 21, 2018
More informationOverview of Aplastic Anemia. Overview of Aplastic Anemia. Epidemiology of aplastic anemia. Normal hematopoiesis 10/6/2017
Overview of Aplastic Anemia Overview of Aplastic Anemia Peter Westervelt, MD, PhD Professor of Medicine Chief, BMT/Leukemia Section Washington University School of Medicine Epidemiology Normal hematopoiesis
More informationCase Report Response of Paroxysmal Nocturnal Hemoglobinuria Clone with Aplastic Anemia to Rituximab
Case Reports in Hematology Volume 212, Article ID 16182, 5 pages doi:1.1155/212/16182 Case Report Response of Paroxysmal Nocturnal Hemoglobinuria Clone with Aplastic Anemia to Rituximab Radha Raghupathy
More informationObjectives. What is Aplastic Anemia. SAA 101: An Introductory Course to Severe Aplastic Anemia
SAA 101: An Introductory Course to Severe Aplastic Anemia David A. Margolis, MD Professor of Pediatrics/Medical College of Wisconsin Program Director/ Children s Hospital of Wisconsin BMT Program Objectives
More informationInternational Journal of Case Reports in Medicine
International Journal of Case Reports in Medicine Vol. 2014 (2014), Article ID 504318, 21 minipages. DOI:10.5171/2014.504318 www.ibimapublishing.com Copyright 2014 Pinar Tosun Taşar, Sevnaz Sahin, Asu
More informationLate Complications Following Treatment for Severe Aplastic Anemia (SAA) with High-Dose Cyclophosphamide (Cy): Follow up of a Randomized Trial
Blood First Edition Paper, prepublished online June 28, 2002; DOI 10.1182/blood-2002-02-0494 Late Complications Following Treatment for Severe Aplastic Anemia (SAA) with High-Dose Cyclophosphamide (Cy):
More informationTransplantation for bone marrow failure: current issues
BONE MARROW FAILURES Transplantation for bone marrow failure: current issues Régis Peffault de Latour Service d Hématologie-Greffe, Hôpital Saint-Louis, Assistance Publique Hôpitaux de Paris (APHP), Paris,
More informationReview of Aplastic Anemia Guidelines. Seiji Kojima MD. PhD.
Review of Aplastic Anemia Guidelines Seiji Kojima MD. PhD. Department of Pediatrics Nagoya University Graduate School of Medicine Chairman of the Severe Aplastic Anemia Working Party Asia-Pacific Blood
More informationSevere Aplastic Anemia in Children and Adolescents. Brigitte Strahm 21. April 2018
Severe Aplastic Anemia in Children and Adolescents Brigitte Strahm 21. April 2018 Acquired Aplastic Anemia in children What is aquired aplastic anemia? Camitta, Blood 1976 How A.L.G. acts is unknown, but
More informationSoliris (eculizumab) For the Treatment of PNH to Reduce Hemolysis
Soliris (eculizumab) You have done well to manage your PNH with Soliris. Living with a rare disease, like PNH, can be challenging, but by sticking with your Soliris therapy, you are doing a lot to help
More informationAnemia (3).ms Hemolytic Anemia. Abdallah Abbadi Feras Fararjeh
Anemia (3).ms4.26.2.18 Hemolytic Anemia Abdallah Abbadi Feras Fararjeh Case 3 24 yr old female presented with anemia syndrome and jaundice. She was found to have splenomegaly. Hb 8, wbc 12k, Plt 212k,
More informationAplastic Anemia Pathophysiology and Approach to Therapy
Aplastic Anemia Pathophysiology and Approach to Therapy BSMCON 2018 Dr. Syed Ghulam Mogni Mowla MBBS, FCPS, FACP Introduction Aplastic anaemia (AA) is the paradigm of the human bone marrow failure syndromes
More informationFDA Report: Eculizumab (Soliris ) for the Treatment of Patients with Paroxysmal Nocturnal Hemoglobinuria
The Oncologist Regulatory Issues: FDA FDA Report: Eculizumab (Soliris ) for the Treatment of Patients with Paroxysmal Nocturnal Hemoglobinuria ANDREW DMYTRIJUK, KATHY ROBIE-SUH, MARTIN H. COHEN, DWAINE
More informationJunfeng Wang 12/10/2010
Paroxysmal Nocturnal Hemoglobinuria. Junfeng Wang 12/10/2010 31 Year Old Female with 11-year History of PNH In 1989, she presented with bleeding & pancytopenia. BM x2 showed AA. Cytogenetic ti was normal.
More informationSESSION 1 Reactive cytopenia and dysplasia
SESSION 1 Reactive cytopenia and dysplasia Falko Fend, Tübingen & Alexandar Tzankov, Basel 1 Disclosure of speaker s interests (Potential) conflict of interest none Potentially relevant company relationships
More informationALXN 1210 for paroxysmal nocturnal haemoglobinuria first line
NIHR Innovation Observatory Evidence Briefing: November 2017 ALXN 1210 for paroxysmal nocturnal haemoglobinuria first line NIHRIO (HSRIC) ID: 12793 NICE ID: 9701 LAY SUMMARY Paroxysmal nocturnal haemoglobinuria
More informationFDA Report: Eculizumab (Soliris ) for the Treatment of Patients with Paroxysmal Nocturnal Hemoglobinuria
FDA Report: Eculizumab (Soliris ) for the Treatment of Patients with Paroxysmal Nocturnal Hemoglobinuria Andrew Dmytrijuk, Kathy Robie-Suh, Martin H. Cohen, Dwaine Rieves, Karen Weiss and Richard Pazdur
More informationOUTCOME AFTER IMMUNOSUPPRESSION
OUTCOME AFTER IMMUNOSUPPRESSION EBMT Aplastic Anemia Educational Meeting Budapest November 1 st 2012 Antonio M. Risitano, M.D., Ph.D. Head of Bone Marrow Transplant Unit Hematology, DBBM Federico II University
More informationPredictive Factors of Mortality in Population of Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH): Results from a Korean PNH Registry
ORIGINAL ARTICLE Oncology & Hematology http://dx.doi.org/1.3346/jkms.216.31.2.214 J Korean Med Sci 216; 31: 214-221 Predictive Factors of Mortality in Population of Patients with Paroxysmal Nocturnal Hemoglobinuria
More informationUnrelated allogeneic transplantation for severe aplastic anemia is a treatment
ARTICLE Stem Cell Transplantation EUROPEAN HEMATOLOGY ASSOCIATION Ferrata Storti Foundation Unrelated alternative donor transplantation for severe acquired aplastic anemia: a study from the French Society
More informationAplastic Anemia: Current Thinking on Disease, Diagnosis and Non- Transplant Treatment
7/23/212 Aplastic Anemia: Current Thinking on Disease, Diagnosis and Non- Transplant Treatment Danielle Townsley, MD, MSc Hematology Branch National, Heart, Lung and Blood Institute National Institutes
More informationAplastic Anemia: Current Thinking on Disease, Diagnosis and Non- Transplant Treatment
4/18/212 Aplastic Anemia: Current Thinking on Disease, Diagnosis and Non- Transplant Treatment Bogdan Dumitriu, MD Hematology Branch National, Heart, Lung and Blood Institute National Institutes of Health
More informationImproved prognosis for acquired aplastic anaemia
158 Department of Haematology and Oncology, Great Ormond Street Hospital for Children NHS Trust, London WC1N 3JH, UK L A Pitcher I M Hann JPMEvans P Veys J M Chessells DKHWebb Correspondence to: Dr Webb.
More informationArticles and Brief Reports
Articles and Brief Reports Stem Cell Transplantation Long-term follow up after allogeneic stem cell transplantation in patients with severe aplastic anemia after cyclophosphamide plus antithymocyte globulin
More information5/21/2018. PNH: Understanding Your Disease and Treatment Options
Patients Surviving (%) 5/2/28 PNH: What s in a Name PNH: Understanding Your Disease and Treatment Options Bart Scott, MD Associate Professor of Medicine, Division of Oncology, University of Washington
More informationNew Insights into Paroxysmal Nocturnal Hemoglobinuria
New Insights into Paroxysmal Nocturnal Hemoglobinuria Robert A. Brodsky Johns Hopkins University School of Medicine, Division of Hematology, Baltimore, MD Correspondence: Robert A. Brodsky, MD, Ross Research
More informationCoding... 5 Benefit Application... 5 Description of Services... 6 Clinical Evidence... 7
TABLE OF CONTENTS Product Variations.... 1 Policy Statement.... 1 Related Policies.... 4 Policy Guidelines..... 4 Coding.... 5 Benefit Application........ 5 Description of Services..... 6 Clinical Evidence.......
More informationCase Report Recurrent and Progressive Abdominal Pain and Enteritis in a Japanese Patient with Paroxysmal Nocturnal Hemoglobinuria
Case Reports in Hematology, Article ID 310750, 4 pages http://dx.doi.org/10.1155/2014/310750 Case Report Recurrent and Progressive Abdominal Pain and Enteritis in a Japanese Patient with Paroxysmal Nocturnal
More informationTrigger Viral/Bacterial infection Immuncomplex induced Hormones Drugs
TMA post SCT Régis Peffault de Latour Bone Marrow Transplant Unit, Saint Louis Hospital, Paris, France 1 TMA post SCT 1. Pathophysiology 2. Clinical characteristics 3. Diagnostic criteria 4. Treatment
More information10/27/2017 PAROXYSMAL NOCTURNAL HEMOGLOBINURIA DANIEL LANDAU, MD PNH TYPICAL CASE
PAROXYSMAL NOCTURNAL HEMOGLOBINURIA Daniel Landau, MD Orlando Health: UF Health Cancer Center Hematologist/ Oncologist Orlando Health University of Florida Cancer Center Section Chief of Hematology/Oncology
More informationParoxysmal Nocturnal Hemoglobinuria: Pathogenesis, Testing, and Diagnosis
September 2013 Volume 11, Issue 9, Supplement 13 Paroxysmal Nocturnal Hemoglobinuria: Pathogenesis, Testing, and Diagnosis Plus a Case Report and a Q&A on the Role of the Hematopathologist Vivek R. Sharma,
More information? Medical mystery? A case report
? Medical mystery? A case report N. Boeckx, MD, PhD 03-10-2017 Case report 34 year male Medical history (Peru) 2014: anemia (Hb 7-8 g/dl) => endoscopy: negative, R/ iron April 2015: acute cholecystitis
More informationClinical Roundtable Monograph
Clinical Roundtable Monograph Clinical Advances in Hematology & Oncology April 2018 Clinical Consequences of Paroxysmal Nocturnal Hemoglobinuria and Aplastic Anemia: A Multidisciplinary Discussion PLUS
More informationCharacteristics of Taiwanese patients of PNH in the international PNH registry
The Author(s) Thrombosis Journal 2016, 14(Suppl 1):39 DOI 10.1186/s12959-016-0094-0 RESEARCH Characteristics of Taiwanese patients of PNH in the international PNH registry Open Access Wen-Chien Chou 1,
More informationImmunosuppressive Therapy and Bone Marrow Transplantation for Aplastic Anaemia The CMC Experience
36 supplement to Journal of the association of physicians of india Published on 1st of every month 1st march, 2015 Immunosuppressive Therapy and Bone Marrow Transplantation for Aplastic Anaemia The CMC
More informationAplastic Anemia: Understanding your Disease and Treatment Options
Aplastic Anemia: Understanding your Disease and Treatment Options No financial relationships or commercial interest related to the content of this presentation Josh Sasine, MD, PhD Hematopoietic Cell Transplant
More informationHow I treat acquired aplastic anemia
How I treat acquired aplastic anemia Phillip Scheinberg and Neal S. Young Blood Volume 120(6):1185-1196 August 9, 2012 2012 by American Society of Hematology Symptoms, Signs, and Lab Findings Bruising,
More informationReduced-intensity Conditioning Transplantation
Reduced-intensity Conditioning Transplantation Current Role and Future Prospect He Huang M.D., Ph.D. Bone Marrow Transplantation Center The First Affiliated Hospital Zhejiang University School of Medicine,
More informationPNH from the perspective of Paediatric Haematologists
EBMT Severe Aplastic Anaemia and Infectious Diseases Working Parties Bruno Rotoli Memorial Educational Course 29 Sept 1 Oct 2014 PNH from the perspective of Paediatric Haematologists Fabio Timeus, MD PhD
More informationLate complications after hematopoietic stem cell transplant in adult patients
Late complications after hematopoietic stem cell transplant in adult patients Gérard Socié, MD, PhD Hematology/Transplantation, Hospital Saint Louis, Paris, France Synopsis H S C T Allogeneic HSCT activity
More informationClinical significance of acquired somatic mutations in aplastic anaemia
Int J Hematol (2016) 104:159 167 DOI 10.1007/s12185-016-1972-8 PROGRESS IN HEMATOLOGY Recent advance in the diagnosis and treatment of bone marrow failure syndromes Clinical significance of acquired somatic
More informationAplastic Anemia. is a bone marrow failure disease 9/19/2017. What you need to know about. The 4 major components of blood
What you need to know about Aplastic Anemia Stuart Goldberg MD Aplastic Anemia is a bone marrow failure disease The bone marrow is the factory that makes blood The 4 major components of blood Red Blood
More informationJPM Presentation January 9, 2018
JPM Presentation January 9, 18 Forward looking statements Statements in this press release about future expectations, plans and prospects, as well as any other statements regarding matters that are not
More informationMDS 101. What is bone marrow? Myelodysplastic Syndrome: Let s build a definition. Dysplastic? Syndrome? 5/22/2014. What does bone marrow do?
101 May 17, 2014 Myelodysplastic Syndrome: Let s build a definition Myelo bone marrow Gail J. Roboz, M.D. Director, Leukemia Program Associate Professor of Medicine What is bone marrow? What does bone
More informationSuccessful use of eculizumab in an 86-year-old patient with paroxysmal nocturnal hemoglobinuria in Japan
Ooe and Nagai SpringerPlus 2014, 3:10 a SpringerOpen Journal CASE STUDY Open Access Successful use of eculizumab in an 86-year-old patient with paroxysmal nocturnal hemoglobinuria in Japan Yokiko Ooe 1*
More informationMedication Prior Authorization Form
Policy Number: 1054 Policy History Approve Date: 06/01/2018 Effective Date: 06/01/2018 Preauthorization All Plans Benefit plans vary in coverage and some plans may not provide coverage for certain service(s)
More informationBorder between aplastic anemia and myelodysplastic syndrome
Int J Hematol (2013) 97:558 563 DOI 10.1007/s12185-013-1324-x PROGRESS IN HEMATOLOGY Advances in the management of acquired aplastic anemia (AA) Border between aplastic anemia and myelodysplastic syndrome
More informationAcute haemolysis and appearance of PNH-like clones in patients with vitamin B12 deficiency and iron deficiency after iron dextran administration
Acute haemolysis and appearance of PNH-like clones in patients with vitamin B12 deficiency and iron deficiency after iron dextran administration Chun-Liang Lin 1, Chin-Chan Lin 1,Wen-Jyi Lo 2,Yu-Chien
More informationSacha Zeerleder, MD PhD Internist-hematologist Academic Medical Centre, Amsterdam Sanquin Research, Amsterdam
Sacha Zeerleder, MD PhD Internist-hematologist Academic Medical Centre, Amsterdam Sanquin Research, Amsterdam Sacha Zeerleder, MD PhD Internist-hematologist Academic Medical Centre, Amsterdam Sanquin Research,
More informationBaseline characteristics and disease burden in patients in the International Paroxysmal Nocturnal Hemoglobinuria Registry
ARTICLES Paroxysmal Nocturnal Hemoglobinuria Baseline characteristics and disease burden in patients in the International Paroxysmal Nocturnal Hemoglobinuria Registry Hubert Schrezenmeier, 1 Petra Muus,
More informationApellis Company Presentation March 2019
Apellis Company Presentation March 219 Forward looking statements Statements in this presentation about future expectations, plans and prospects, as well as any other statements regarding matters that
More informationCorporate Medical Policy
Corporate Medical Policy File Name: Origination: Last CAP Review: Next CAP Review: Last Review: eculizumab_soliris 8/2014 4/2018 4/2019 4/2018 Description of Procedure or Service Paroxysmal nocturnal hemoglobinuria
More information